At the Congress of Autoimmunity, held in Slovenia in May 2010, more than 1500 papers were presented that focused on both organ-specific and general autoimmunity. The central theme of the Congress was the role of environment and autoimmunity, and the resulting series of papers drew attention to the relationship between the environment and autoimmune responses. In this issue, we focus on the mosaic of autoimmunity and present a series of papers that we think are unique contributions to the subject of immunobiology. The basic and clinical issues addressed herein are important to understanding genetic susceptibility to the development of autoimmunity. For example, the increased concordance in monozygotic, as compared with dizygotic, twins and the increased prevalence of affected family members have been documented in many diseases. 43 The most potent genetic influence on autoimmunity is via the major histocompatibility complex (MHC), although non-MHC-susceptible alleles have also been documented, 44, 45 and a plausible role for gene therapies in autoimmune diseases has been suggested. 20 In this issue, Proal et al. utilize metagenomics to present a novel approach to deciphering the secrets of human autoimmunity and a promising new approach to treating autoimmune diseases. The authors suggest that the up-and downregulation of human genes by different infectious agents alters the host's natural homeostatic state, eventually leading to autoimmunity.
Infectious agents are perhaps the most common environmental factors associated with autoimmune diseases, and genetic variability is a well-known link between the two. 46 The multifaceted associations between infections and autoimmunity may be either pathogenic or protective. In other words, infectious agents may induce a certain autoimmune disease in a genetically susceptible individual while protecting that same individual from another disease. 32, 47, 48 In this issue, Christen et al. review recent evidence that viruses might on the one hand be involved in the pathogenesis of type 1 diabetes mellitus and on the other hand induce a state of protection from autoimmunemediated damage.
Other environmental factors, such as ultraviolet light, 24 49 in general and particularly the Gulf War syndrome and macrophagic myofascitis, and manifestations associated with silicone implants. 50, 52 Most exposures to environmental factors are variable and can be avoided or altered once an individual risk of autoimmunity has been determined. For instance, changes in diet or nutritional supplementation may be beneficial for certain immune-mediated conditions. 36 In this issue, Selmi et al. report on the ability of Spirulina, a blue-green alga, to alter immune responses among senior citizens with a history of anemia.
Central elements of the mosaic of autoimmunity are hormonal factors such as estrogen 53 and prolactin. 54 Recently, the linkage between another hormone, vitamin D and autoimmunity has become a focus of attention. [55] [56] [57] [58] Low levels of this vitamin were associated with several autoimmune diseases and their specific manifestations. Herein, Kivity et al. describe an association between low levels of vitamin D and autoimmune thyroid disease, and Vadacca et al. delineate the role of leptin in autoimmune rheumatic diseases.
It is interesting to note the evolution within the Congresses of Autoimmunity and compare that to the increased international recognition of autoimmunity as a critical health issue. Indeed, it is estimated that as a group, autoimmune diseases represent somewhere in the range of 11-21% of the population, with type I diabetes and autoimmune thyroid disease at the top of the list. In fact, there is increasing evidence that there is an increase in autoimmune disease and certainly this is the case for type I diabetes. However, it is equally the case that as Western society has developed and, in particular, as hygiene has improved, that there have been corresponding increases in the socalled autoinflammatory diseases of the gut such as inflammatory bowel disease and Crohn's disease. If one were to examine the literature in 1974, it is clear that there were perhaps a total of 30-40 autoimmune diseases. On the other hand, in 2007, it was suggested that everything is autoimmune until proven otherwise. The implication meant by this statement is that secondary bystander mechanisms, whether non-specific inflammatory or adaptive responses had a major role in modulating a variety of diseases, even including those diseases not characterized by a primary loss of tolerance. An example of this is atherosclerotic heart disease.
There are now more than 100 autoimmune diseases and perhaps best exemplified by this explosive increased recognition, is the antiphospholipid antibody syndrome. This disease was not even known until the early 1970s, when first described in a population of women in Jamaica, but has since become a major health issue throughout the world and has emphasized the multidisciplinary nature of autoimmunity. For example, whereas autoimmunity was once the field primarily of rheumatologists, it now includes, in the case of antiphospholipid antibody syndrome, gynecologists and obstetricians. We have in fact suggested that there is a need for a new discipline called autoimmunology and we argue that such an individual would likely come from a rheumatologic background and will be valuable in not only the diagnosis but especially the use of the biologics in the treatment of multiple autoimmune diseases. At our institution, for example, it is the rheumatologist who is the primary advisor not only for the connective tissue diseases, but also for the use of biologics in neurology and gastroenterology.
This issue of the biologics also raises the importance of new therapies. In 1974, cyclophosphamide was introduced as a primary treatment of rheumatic disease. At the time it was suggested that 'since its original production in subsequent early studies, the clinical use of cyclophosphamide has been extended from limited research in neoplastic diseases to such diverse disorders as rheumatoid arthritis, lupus erythematosus and other autoimmune diseases'. 59 Indeed, had it been suggested in 1974 that cyclophosphamide would still be in use in 2007, we would have thought it impossible. But possible it is and, in fact, the use of cyclophosphamide has opened the way for numerous other immunosuppressive drugs, the majority with significantly more selectivity and less toxicity. More importantly, these early attempts at modulating immunity have given way to the biologics, the use of intravenous immunoglobulin and numerous combinations designed to help patients with autoimmune disease.
There are at least a dozen textbooks of physiology that are used in medical schools throughout Europe and North America and likely a similar number in Asia and South America. In fact, to any physician and scientist, physiology is the very basis of medicine and studied in the primary curricula of every medical school in the world in 2010, much as it was in 1910. Yet, interestingly, although these textbooks have sections on circulation and respiration, there is a not a single chapter that discusses in any depth the immune system. The only exceptions are lymphatic organs and, in some of the better textbooks, discussions of cell biology. On the other hand, the words 'immunology' and 'autoimmunity' can be found in any textbook of human medicine, whether it is family practice, orthopedics, internal medicine or cardiology. This is an issue that must change in basic science curricula as an understanding of the immunological physiology is critical if one is to interpret newer diagnostic tests.
In fact, discussion of newer diagnostic tests has always been a theme of the Congress of Autoimmunity. It was noted in a recent paper that 'The history of immunology as a discipline per se can be traced back to the spectrum of infectious diseases and allergy'. It was not until later that the conceptual revolution began in defining the nature of tolerance and the distinction between self and non-self thanks to the Nobel laureate Paul Ehrlich. Ehrlich became famous not so much for his contributions in autoimmunity, but rather because he coined 'The Horror Autotoxicus' stating that an immune response against one's own body elements would necessarily lead to death; the concept of autoimmunity can be traced back to these years. 60, 61 Following the 1947 discovery of lupus erythematosus cells and later of serum antinuclear antibodies, it became clear that there are not only multiple autoimmune diseases, but also that autoantibodies are more numerous than autoimmune diseases. Our knowledge on autoimmunity has paralleled the fast pace of discovery for new diagnostic tools 62 and we are currently in the era of microarrays to diagnose and ideally predict autoimmunity. [63] [64] [65] We expect that the next Congress of Autoimmunity will focus not only on diagnostics but especially on newer therapeutics. We emphasize that there is significant justification for autoimmunology as a specialization. Indeed, our ability to treat autoimmune diseases now appears to be almost independent of knowing their etiology. The best example of this is rheumatoid arthritis. Although studies of identical twins have led to an enormous understanding of shared epitopes and the genetic basis of autoimmunity and rheumatoid arthritis in particular, it still leaves a void in what the next steps will be in therapeutics. Despite this, the improvement in health care in rheumatoid arthritis has been nothing less than outstanding. The use of the biologics has completely changed standard of care not only for the important issues of joint protection and reduction of erosions, but also commanding a key need to understand toxicity in both short-and long-term side effects. We have always needed to be vigilant to tuberculosis and other opportunistic infections in such patients, but now the vigilance is even more striking and demanding. In fact, the side effects of the biologics such as progressive multifocal leukoencephalopathy, have raised entirely new issues that were previously either unknown or not critical to the rheumatologist or indeed to nearly any physician involved in autoimmunity. We fully expect better and more efficacious biologics that will target specific defects and reducing the short-and long-term side effects. Progress in systemic lupus has lagged. Studies of patients with lupus have revealed data that are of value not only in adaptive immunity, but also in innate immunity, apoptosis, primary T-and B-cell abnormalities, and even maternal fetal interactions. The diagnosis of lupus nephritis has approached considerably more sophistication but ironically, as alluded to the above, we are still using cyclophosphamide. Even with the newer The mosaic of autoimmunity N. Agmon-Levin et al 190 immunosuppressive drugs, we are still very much behind in better treatments of lupus patients and we still await efficacious biologics that hold opportunities to the majority of patients with lupus. Indeed, health care costs are enormous for patients with autoimmune disease and reflect a great challenge for communities.
We also expect increased study of the geoepidemiology of autoimmunity. This was emphasized in the current congress and we believe will be re-emphasized in the future. Geoepidemiology affords us not only the ability to study disease prevalence and incidence but, more importantly, environmental factors. The use of sera banks has disclosed that the serologic abnormalities of specific autoimmune diseases can precede pathology by a decade or longer. This is well exemplified in studies of systemic lupus, rheumatoid arthritis and primary biliary cirrhosis. Geoepidemiology also includes dissection of the genetic predisposition and we note the valuable contributions of candidate genes and, more recently, genome-wide associations. However, genome-wide associations must now give way to deep sequencing. Deep sequencing was not a subject in any one of the nearly 2000 abstracts at the Congress of Autoimmunity in Slovenia, but we fully anticipate that it will become an increasing theme of future congresses. Just as immunologists had to learn and become experts in the technology of recombinant DNA, so will they need to become experts in bioinformatics and interpretation of DNA data.
This interest in bioinformatics is important not only for the researcher, but also for the clinician. Genetic counseling was once reserved for the pediatricians to counsel parents of children regarding future risks of diseases such as cystic fibrosis. However, with the increased ability to predict autoimmune disease and especially with the explosive field of genomics, we anticipate that genetic counseling may well become an issue in rheumatology and immunology. However, this does not end with bioinformatics of genomics. To complicate this equation is the issue of epigenetics. We know, for example, that DNA modification occurs after birth and there is increased recognition that epigenetic changes occur in rheumatoid arthritis and lupus. However, the functional significance of those epigenetic changes is less clear. In fact, the technology of epigenetics is in its infancy and there is a need for standardization, vigorous definitions and evidence-based large-scale studies if epigenetics is to make a contribution and if it is important either for diagnosis or for the natural history of disease.
Thus, modern life and exposures to novel chemical and xenobiotic compounds may lead to the development of new complexes of symptoms that do not necessarily belong to one of the well-known autoimmune diseases. As physicians and scientists, we must continue to study novel pathogenic mechanisms and susceptible alleles to help us identify new therapeutic venues.
